The US Food and Drug Administration has approved gabapentin enacarbil for the treatment of restless legs syndrome in adults. The drug was developed by XenoPort Inc of the US. GlaxoSmithKline Plc is a commercial partner. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
